ABIOMED reported a GAAP loss of $26.525 million for 3 months of fiscal year 2022, compared to a profit of $44.588 million in the previous year. Revenue increased 53.2% to $252.585 million compared to $164.85 million a year earlier.
ABIOMED reported a GAAP loss of $26.525 million for 3 months of fiscal year 2022, compared to a profit of $44.588 million in the previous year. Revenue increased 53.2% to $252.585 million compared to $164.85 million a year earlier. 
investors.abiomed.com
English (US) 